What's New in ScreenMyGene: The 2026 Platform Update
Short answer: ScreenMyGene's latest platform release adds an ENFD workflow for small-fiber neuropathy evaluation, an MME/ORT opioid-safety calculator, a bilingual voice assistant, and a built-in Medicare coverage reference spanning NCDs plus Novitas and First Coast LCDs — alongside the OCR batch pipeline, prior-testing verification, and integrated clinical trials and PubMed search. Every addition serves the same goal: order-ready, coverage-defensible genetic testing decisions in a single pass.
Why this release matters now
The market context is stark. Avalon's 2026 Lab Trend Report found genetic testing spend jumped 35% year over year against only a 22% rise in utilization — payers are watching this gap, and coverage scrutiny is tightening accordingly. Meanwhile, labs using AI-driven pre-claim tools are holding near-99% first-pass clean-claim rates while everyone else fights rising denials. The direction of travel is unambiguous: the labs that win are the ones that validate before the order, not after the remittance. This release pushes more of that validation into the single pass ScreenMyGene already performs.
What's new in the platform
ENFD workflow
A dedicated module supporting epidermal nerve fiber density evaluation — extending ScreenMyGene's neurology coverage into small-fiber neuropathy workups, where structured documentation and appropriate test sequencing matter for both clinical quality and coverage.
MME/ORT opioid-safety calculator
Morphine milligram equivalent calculation and Opioid Risk Tool scoring, built into the analysis workspace. For charts where pharmacogenomic testing intersects with opioid therapy — CYP2D6 and codeine or tramadol, for instance — opioid exposure context now lives beside the drug–gene reasoning instead of in a separate tool.
Ask ScreenMyGene, in English and Spanish
A hands-free voice assistant answers questions like “show qualified panels” or “find trials for pancreatic cancer” — and “muestra los calificados” — without leaving the analysis. Bilingual support meets clinical teams where they actually work.
Medicare coverage reference, built in
National Coverage Determinations plus LCDs and billing articles for Novitas Solutions and First Coast Service Options, with key billing and coverage alerts surfaced beside every recommendation. The policy that governs payment is now one glance away from the panel it governs. For the full mechanics, see our guide to Medicare coverage for genetic testing.
Hardened intake: OCR review, batch, and prior-testing verification
Scanned records pass through OCR with a human review step before anything is analyzed; batch mode processes up to five patients in one reviewable pass; and Medicare's once-in-a-lifetime rule for equivalent germline NGS testing is enforced at intake, with documented justification required before any re-order proceeds — the duplicate-testing failure we flagged in our denials analysis, closed at the front door.
Evidence and research, one click away
Integrated ClinicalTrials.gov and PubMed search puts recruiting trials and current molecular-genetics literature in the same workspace as the recommendation, so a qualifying patient can be matched to research options in the same session.
Audit-ready by default
Every analysis lands in a reviewable history with PDF export; administrators control user roles and module access with a full audit log. Decision support that can show its work is decision support a medical director can stand behind.
The through-line
None of these are bolt-ons. Each one removes a reason an order fails downstream: a missing coverage check, an undocumented prior test, an unstructured scan, a reviewer who can't trace the reasoning. That is the platform's thesis — one inspectable pass from unstructured chart to defensible, coverage-aligned recommendation.
Frequently asked questions
What is ENFD and why does it matter for genetic testing workflows?
Epidermal nerve fiber density evaluation supports the workup of small-fiber neuropathy. Structured ENFD documentation strengthens both the clinical picture and the medical-necessity record around neurology-related genetic testing decisions.
What is the MME/ORT calculator?
It computes morphine milligram equivalents and Opioid Risk Tool scores inside the analysis workspace, giving opioid-exposure context alongside pharmacogenomic reasoning for drug–gene pairs like CYP2D6 and codeine.
Which Medicare contractors does the coverage reference include?
National Coverage Determinations plus Local Coverage Determinations and billing articles for Novitas Solutions and First Coast Service Options, with billing and coverage alerts surfaced in-workflow.
Does the voice assistant require special hardware?
No — it runs in the platform with a hold-to-speak control and supports English and Spanish.
How do I see the new features?
Current users: log in at app.screenmygene.com — the modules are live. New to ScreenMyGene: request a demo at support@screenmygene.com.
Feature availability may vary by deployment and subscription. ScreenMyGene is clinical decision support intended to assist qualified healthcare professionals; it does not provide a diagnosis and does not replace independent clinical judgment.
Sources: Avalon 2026 Lab Trend Report (diagnostic spend vs. utilization); industry reporting on AI-assisted claims and denial prevention, 2026.